Literature DB >> 3643105

Vancomycin for treatment of infections with methicillin-resistant Staphylococcus aureus: are there alternatives?

D Milatovic.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3643105     DOI: 10.1007/BF02013306

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


× No keyword cloud information.
  34 in total

1.  Emergence of rifampin-resistant strains of Staphylococcus aureus during combination therapy with vancomycin and rifampin: a report of two cases.

Authors:  G L Simon; R H Smith; M A Sande
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

2.  Teicoplanin.

Authors:  A H Williams; R N Grüneberg
Journal:  J Antimicrob Chemother       Date:  1984-11       Impact factor: 5.790

3.  In vitro activity of N-formimidoyl thienamycin and other beta-lactam antibiotics against methicillin-resistant Staphylococcus aureus.

Authors:  R L Thompson; K A Fisher; R P Wenzel
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

4.  Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis.

Authors:  M A Tamer; J D Bray
Journal:  Clin Pediatr (Phila)       Date:  1982-02       Impact factor: 1.168

5.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Methicillin-resistant Staphylococcus aureus: microbiologic characteristics, antimicrobial susceptibilities, and assessment of virulence of an epidemic strain.

Authors:  J E Peacock; D R Moorman; R P Wenzel; G L Mandell
Journal:  J Infect Dis       Date:  1981-12       Impact factor: 5.226

7.  Bacteremia due to methicillin-resistant Staphylococcus aureus.

Authors:  J P Myers; C C Linnemann
Journal:  J Infect Dis       Date:  1982-04       Impact factor: 5.226

8.  Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to beta-lactam antibiotics in vivo and in vitro.

Authors:  H F Chambers; C J Hackbarth; T A Drake; M G Rusnak; M A Sande
Journal:  J Infect Dis       Date:  1984-06       Impact factor: 5.226

9.  Comparison of the activities of coumermycin, ciprofloxacin, teicoplanin, and other non-beta-lactam antibiotics against clinical isolates of methicillin-resistant Staphylococcus aureus from various geographical locations.

Authors:  K E Aldridge; A Janney; C V Sanders
Journal:  Antimicrob Agents Chemother       Date:  1985-11       Impact factor: 5.191

10.  Antibacterial activity of coumermycin alone and in combination with other antibiotics.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

View more
  4 in total

1.  Excretion of beta-lactam antibiotics in sweat--a neglected mechanism for development of antibiotic resistance?

Authors:  N Hoiby; C Pers; H K Johansen; H Hansen
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

2.  Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users.

Authors:  P M Small; H F Chambers
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

3.  Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome.

Authors:  T J Walsh; H C Standiford; A C Reboli; J F John; M E Mulligan; B S Ribner; J Z Montgomerie; M B Goetz; C G Mayhall; D Rimland
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

4.  Antibiotic susceptibility and phage typing of methicillin-resistant Staphylococcus aureus clinical isolates from blood cultures of 692 patients in 15 Israeli hospitals.

Authors:  Z Samra; R Gadba
Journal:  Eur J Epidemiol       Date:  1993-09       Impact factor: 8.082

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.